The Board of Trustees takes stock of finalised research projects and new channels of research
The Barcelona Macula Foundation yesterday hosted the annual meeting of its Board of Trustees, which took stock of the research projects being undertaken and those that have reached a conclusion. It also analysed those that the Barcelona Macula Foundation aims to implement in the immediate future.
With regard to the projects that have been finalised, Dr Jordi Monés, Director, principal investigator and one of the Barcelona Macula Foundation founding trustees, explained the results of the EYERISK and ADVANCE(CAT) projects. These concluded recently with the commitment of the research participants to keep progressing in the channels opened by their results.
In terms of the projects that remain in progress, the focus was placed on MICROB-EYE-OME, REGENERATIVE STEM CELLS THERAPIES and PHASE I/II a CLINICAL TRIAL of hESC. The aim of these research projects is to help deliver new therapies to halt the progression of diseases like retinitis pigmentosa and Age-Related Macular Degeneration (AMD).
In addition to learning of the status of these pioneering projects researching into degenerative retinal diseases, the Board analysed the impact of the informative campaigns that publicise among professionals, the media and patients the different pieces of research and other initiatives like the Silver Project (Smart Aids for Visually Impaired).
The Barcelona Macula Foundation is a benchmark organisation that boasts 20 years of research working alongside institutions and corporations linked to the scientific elite. Its mission is to reverse vision pathologies that currently lack a cure.